DSIP: Evidence, Mechanism, Dosing & 2026 FDA Status

DSIP ("delta sleep-inducing peptide"; proposed nonproprietary name emideltide) is a naturally occurring nine-amino-acid neuropeptide first isolated in the mid-1970s from the cerebral venous blood of sleeping rabbits by the Swiss Schoenenberger-Monnier group.58 It is marketed today as a clean sleep, recovery, cortisol and longevity peptide. This monograph separates what has actually been studied in humans from what has been extrapolated or hyped.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. DSIP is not an FDA-approved drug; it is sold "for research use only — not for human consumption." Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is DSIP and how does it work?

DSIP is a hydrophilic, amphiphilic nonapeptide, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), molecular weight about 849 to 850 daltons.8 It was identified from the cerebral venous blood of rabbits whose thalamus was electrically stimulated to induce sleep; the name reflects the observation that natural and synthetic DSIP enhanced delta-wave (slow-wave) and spindle EEG activity when infused into recipient animals.5

The mechanism is the central caveat of the entire literature. After roughly 50 years, no specific DSIP receptor, gene, or precursor protein has ever been identified.7 Proposed actions are mostly preclinical: in-vitro work suggests DSIP enhances GABA-activated currents while blunting NMDA-receptor excitation, implying a net excitation-dampening effect; it does not bind opioid receptors directly but appears to influence the endogenous opioid system, with naloxone-reversible effects in animal sleep models — the rationale for its withdrawal use.8 An authoritative 1986 review concluded the most probable common pathway was modulation of adrenergic transmission, while stating plainly that the mechanism remains to be established.5 DSIP is rapidly degraded, with an in-vitro half-life of roughly 15 minutes — which partly explains the use of IV infusion in the clinical trials and the temporally narrow effect windows observed.8

What is the evidence by indication?

What has actually been studied in humans is roughly a dozen people across two double-blind crossover sleep trials, plus about 107 unblinded withdrawal patients and 7 pain patients in uncontrolled series. Every indication below should be read with those sample sizes in mind.

The sleep data are the strongest. In healthy volunteers (n=6, double-blind crossover), slow IV DSIP at 25 nmol/kg increased daytime sleep by about 59 percent over the 130 minutes after dosing versus placebo, shortened subsequent night sleep onset, and improved sleep efficiency — without classic pharmacologic sedation on EEG; the authors framed DSIP as sustaining natural sleep functions rather than sedating.1 In chronic insomniacs (n=6, double-blind), acute IV DSIP produced longer sleep duration, fewer interruptions and slightly more REM, with effects appearing in the second hour and a described normalizing influence on human sleep regulation.2 The caveats are severe: the samples are minuscule, the work is about 45 years old, results across the broader literature are mixed, some studies find no DSIP-slow-wave-sleep correlation at all, and no modern adequately powered RCT exists — recent supportive work is a DSIP-fusion peptide in a PCPA-induced insomnia mouse model.710 A single case report describes DSIP advancing a phase-shifted sleep cycle and enabling benzodiazepine withdrawal.9

The withdrawal and pain reputation is far weaker than it looks. In 107 inpatients (60 opiate-, 47 alcohol-dependent) given IV DSIP, withdrawal symptoms reportedly disappeared or improved markedly in about 97 percent of opiate-dependent and 87 percent of alcohol-dependent patients — but these series had no control group and no blinding, fatal flaws for an endpoint dominated by spontaneous resolution and placebo response, so the striking percentages are hypothesis-generating only.311 In 7 pain patients, pain fell in 6 of 7, but again with no concurrent control or blinding.4 And the popular cortisol claim is actively contradicted: in a controlled human study, IV DSIP did not affect CRH-stimulated or meal-induced ACTH and cortisol in healthy men.6 The longevity and anti-tumor story is mouse-only and frequently over-marketed.8

What doses appear in the literature?

Reported strictly as information, not a protocol. The controlled sleep trials used 25 nmol/kg by slow IV infusion in both healthy volunteers and chronic insomniacs — roughly 21 micrograms per kilogram of the ~849-dalton peptide, i.e. low-microgram-per-kg dosing, not milligram dosing.12 The withdrawal series used repeated IV courses, with opiate-dependent patients needing more injections than alcohol-dependent patients.3 The pain series used IV DSIP, five consecutive daily injections then five every 48 to 72 hours.4 The controlled evidence is entirely intravenous; the subcutaneous route common in present-day grey-market use is not supported by controlled trials and has no validated dose. Because there is no FDA-approved DSIP product there is no authoritative label, sterility standard, or reconstitution guidance — a key safety gap — and the ~15-minute half-life means single peripheral injections may not reproduce the infusion conditions of the original trials.8

How safe is DSIP?

Human safety data are limited and short-term. Across the small studies DSIP was generally well tolerated: no daytime sedation in the sleep trials, and good tolerability in the withdrawal series apart from headache in a few patients.23 A notable and counterintuitive signal: used as an anesthesia adjunct, DSIP unexpectedly increased heart rate and reduced anesthetic depth rather than deepening sedation — a paradoxical finding for any sedative-positioned compound.8 Long-term safety is unknown; there are no standardized chronic human safety studies, and immunogenicity and the effects of repeated peripheral injection are unstudied — explicitly the basis for DSIP's prior FDA Category-2 placement.15 Theoretical interactions with sedatives, opioids or alcohol are plausible but unstudied, and pregnancy, lactation and pediatric use are precautionary avoid populations because there is no approved label. In practice a large real-world risk is product quality: grey-market DSIP sold for research use only has unassured purity, identity, sterility and endotoxin content. Readers can verify the regulatory record directly at the FDA's July 2026 PCAC meeting page.

What is the FDA and WADA status in 2026?

DSIP is not an FDA-approved drug and has no marketing authorization for any indication.12 The 2026 timeline is the headline: on April 15, 2026 the FDA removed twelve peptides — including emideltide (DSIP) — from 503A Category 2, the list of bulk substances flagged as raising significant safety concerns for compounding.1314 Removal lifts the explicit prohibition designation but does not authorize compounding; that requires separate Pharmacy Compounding Advisory Committee review and an FDA decision.13 At the PCAC meeting on July 23-24, 2026, the committee is scheduled to evaluate emideltide (free base and acetate) for possible inclusion on the 503A Bulk Drug Substances List, with FDA naming opioid withdrawal, chronic insomnia and narcolepsy as the uses to be weighed.12 Three statuses remain distinct: off Category 2 is not the same as on the authorized bulks list, which is not the same as an FDA-approved drug.15

For athletes the picture is less clear-cut than for many peptides. DSIP is not listed by name on the WADA Prohibited List. However, the S2 class (peptide hormones, growth factors and related substances and mimetics) contains broad catch-all language, WADA status is independent of FDA legality, and the secondary-source basis here warrants caution — any WADA-tested athlete should verify current status with their anti-doping organization before use.16 DSIP is not a DEA-controlled substance.

Bottom line. DSIP is a genuinely interesting endogenous neuropeptide whose human evidence is thin, old and small, and whose mechanism is, after half a century, still not pinned to any identified receptor, gene or precursor. From a root-cause, evidence-first standpoint it is best regarded as a promising but unproven investigational compound — graded B for a modest sleep effect, with the most consequential 2026 development being regulatory rather than new efficacy data. Regulatory facts here are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.